Mark N Lurie1, Kipruto Kirwa2, Julia Callaway1, Morna Cornell3, Andrew Boulle3, Angela M Bengtson1, Mariette Smith3, Natalie Leon4, Christopher Colvin5. 1. Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA. 2. Department of Environmental Health, Tufts University, Medford, OR, USA. 3. Department of Health, Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa. 4. Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa. 5. Division of Social and Behavioural Sciences, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Abstract
OBJECTIVES: To quantify the HIV care cascade in a Cape Town sub-district to understand rates of linkage to and engagement in HIV care. METHODS: We used routinely collected data to reconstruct the treatment cascade for 8382 infected individuals who tested HIV + in 2012/2013. We obtained data on patient gender, year of initial HIV-positive test, age at testing and initial CD4 cell count and defined five stages of the HIV care cascade. We quantified attrition across cascade stages. RESULTS: Two-thirds of the sample (5646) were women. Men were older at time of first testing (36.5 vs. 31.3 years) and had more advanced HIV disease at diagnosis (298 vs. 404 CD4 cells/µL for women). The median duration of follow-up was 818 days. Among women, 90.5% attended an initial HIV care visit, 54.6% became eligible for antiretroviral therapy under local guidelines during follow-up, 49.3% initiated ART and 45.6% achieved a therapeutic response. Among men, 88.0% attended an initial HIV care visit, 67.4% became ART eligible during follow-up, 48.0% initiated ART and 42.4% achieved a therapeutic response. Approximately 3% of women and 5% of men died during follow-up. CONCLUSIONS: We were able to reconstruct the HIV treatment cascade using routinely collected data. In this setting, rates of engagement in care differ by gender in key stages of the cascade, with men faring worse than women at each cascade point. This highlights the need for interventions aimed at encouraging earlier testing, linkage, ART initiation and retention among men.
OBJECTIVES: To quantify the HIV care cascade in a Cape Town sub-district to understand rates of linkage to and engagement in HIV care. METHODS: We used routinely collected data to reconstruct the treatment cascade for 8382 infected individuals who tested HIV + in 2012/2013. We obtained data on patient gender, year of initial HIV-positive test, age at testing and initial CD4 cell count and defined five stages of the HIV care cascade. We quantified attrition across cascade stages. RESULTS: Two-thirds of the sample (5646) were women. Men were older at time of first testing (36.5 vs. 31.3 years) and had more advanced HIV disease at diagnosis (298 vs. 404 CD4 cells/µL for women). The median duration of follow-up was 818 days. Among women, 90.5% attended an initial HIV care visit, 54.6% became eligible for antiretroviral therapy under local guidelines during follow-up, 49.3% initiated ART and 45.6% achieved a therapeutic response. Among men, 88.0% attended an initial HIV care visit, 67.4% became ART eligible during follow-up, 48.0% initiated ART and 42.4% achieved a therapeutic response. Approximately 3% of women and 5% of men died during follow-up. CONCLUSIONS: We were able to reconstruct the HIV treatment cascade using routinely collected data. In this setting, rates of engagement in care differ by gender in key stages of the cascade, with men faring worse than women at each cascade point. This highlights the need for interventions aimed at encouraging earlier testing, linkage, ART initiation and retention among men.
Keywords:
Afrique du Sud; HIV treatment cascade; South Africa; cascade de traitement du VIH; différences entre les sexes; gender differences; lien avec les soins; linkage to care
Authors: Morna Cornell; Michael Schomaker; Daniela Belen Garone; Janet Giddy; Christopher J Hoffmann; Richard Lessells; Mhairi Maskew; Hans Prozesky; Robin Wood; Leigh F Johnson; Matthias Egger; Andrew Boulle; Landon Myer Journal: PLoS Med Date: 2012-09-04 Impact factor: 11.069
Authors: Nicholas A Medland; James H McMahon; Eric P F Chow; Julian H Elliott; Jennifer F Hoy; Christopher K Fairley Journal: J Int AIDS Soc Date: 2015-11-30 Impact factor: 5.396
Authors: Eduard J Beck; J Mark Shields; Gaurang Tanna; Gerrit Henning; Ian de Vega; Gail Andrews; Philippe Boucher; Lionel Benting; Jesus Maria Garcia-Calleja; John Cutler; Whitney Ewing; Boonchai Kijsanayotin; Tapiwanashe Kujinga; Mary Mahy; Keletso Makofane; Kim Marsh; Chujit Nacheeva; Noma Rangana; Mary Felissa Reyes Vega; Keith Sabin; Olga Varetska; Steven Macharia Wanyee; Stephen Watiti; Brian Williams; Jinkou Zhao; Cesar Nunez; Peter Ghys; Daniel Low-Beer Journal: Glob Health Action Date: 2018 Impact factor: 2.640
Authors: Gesine Meyer-Rath; Leigh F Johnson; Yogan Pillay; Mark Blecher; Alana T Brennan; Lawrence Long; Harry Moultrie; Ian Sanne; Matthew P Fox; Sydney Rosen Journal: PLoS One Date: 2017-10-30 Impact factor: 3.240
Authors: Eugene T Richardson; Sean E Collins; Tiffany Kung; James H Jones; Khai Hoan Tram; Victoria L Boggiano; Linda-Gail Bekker; Andrew R Zolopa Journal: J Int AIDS Soc Date: 2014-06-27 Impact factor: 5.396
Authors: Angela M Bengtson; Ana Lucia Espinosa Dice; Kipruto Kirwa; Morna Cornell; Christopher J Colvin; Mark N Lurie Journal: AIDS Behav Date: 2021-02-20
Authors: Angela M Bengtson; Christopher Colvin; Kipruto Kirwa; Morna Cornell; Mark N Lurie Journal: Trop Med Int Health Date: 2020-06-08 Impact factor: 2.622
Authors: Ana Lucia Espinosa Dice; Angela M Bengtson; Kevin M Mwenda; Christopher J Colvin; Mark N Lurie Journal: BMJ Open Date: 2021-12-02 Impact factor: 2.692